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ABSTRAK 
 
Satu siri kes retrospektif untuk menyelidik peranan dan keselamatan suntikan pre-
operatif faktor anti-vascular endothelial growth (anti-VEGF) ranibizumab “LUCENTISTM” 
untuk pesakit yang mengidap penyakit retinopati diabetes yang perlu menjalani 
pembedahan vitrektomi telah dijalankan. Siri ini melibatkan dua puluh mata konsekutif 
dari 16 pesakit yang menerima suntikan tersebut 3 hingga 8 hari (purata 4.4 hari) 
sebelum vitrektomi untuk retinopati diabetis. Umur pesakit adalah dalam lingkungan 46 
hingga 72 tahun (purata 57.7 tahun). Tiada berlaku sebarang komplikasi setempat 
ataupun sistemik. Indikasi untuk vitrektomi adalah retinal detachment (RD) [n=11; 3 
kombinasi tractional (TRD) - rhegmatogenous RD (RRD), 8 TRD], TRD dengan 
pendarahan vitreus (VH) (n=3) ,VH (n=8) dan sindrom traksi vitreo-makular (n=1). 
Kriteria kemasukan ialah semua kes konsekutif yang menjalani vitrektomi yang ulung-
ulung kali menerima suntikan anti-VEGF sebelum pembedahan. Tahap penglihatan (VA) 
sebelum pembedahan ialah 6/36 hingga persepsi cahaya. Semua mata berdarah 
dengan kadar minima ke sederhana semasa pembedahan. Pendarahan (VH) selepas 
pembedahan dalam mata yang tiada tamponad ataupun tamponad gas adalah tiada 
(n=1), minima (n=13) ataupun sederhana (n=1). Tahap pendarahan pada mata berisi 
minyak silikon pula adalah tiada (n=1), sederhana (n=3) ataupun pendarahan teruk 
(n=1). Tahap penglihatan (VA) post-operatif adalah tidak berubah (n=2) (10%), lebih baik 
(n = 14) (70%) ataupun berkurangan (n=4). VA adalah 2/60 atau lebih baik (n=15) 
hingga tiada persepsi cahaya (n=1). Dua mata mencapai VA sebaik 6/12 (10%). Sepuluh 
mata (50%) mencapai 6/36 atau lebih baik. Kesimpulannya ialah suntikan pre-operatif 
intravitreal ranibizumab adalah selamat dan berkesan digunakan untuk pembedahan 
vitrectomi diabetik dan berupaya mengurangkan pendarahan perioperatif sejurus 
mampu memulihkan penglihatan pesakit. 
 
Kata kunci:  Ranibizumab, adjuvan, retinopati diabetis, vitrektomi 
ABSTRACT  
 
 A retrospective case series review was conducted to determine the pre-operative role 
and safety of pre-operative adjunctive anti-vascular endothelial growth factor (anti-
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VEGF) agent ranibizumab “LUCENTISTM” in patients with diabetic retinopathy requiring 
vitrectomy. The study involved twenty consecutive eyes of sixteen patients (age range: 
46-72 years; mean 57.5 years) which received intravitreal injection of 0.5 - 1 mg of 
ranibizumab 3 to 8 days (mean 4.4 days) prior to vitrectomy for diabetic retinopathy. 
There were no local or systemic post-injection complications. Indications for vitrectomy 
were retinal detachment (RD) [n=11; 3 combined tractional (TRD) - rhegmatogenous RD 
(RRD), 8 TRD], TRD with vitreous haemorrhage (VH) (n=3) ,VH (n=8) and vitreo-
macular traction syndrome (n=1). Inclusion criteria include all consecutive eyes of 
diabetic patients requiring vitrectomy receiving a first pre-operative injection of anti-
VEGF. Pre-operative visual acuity (VA) ranged from 6/36 to light perception. All eyes had 
minimal to moderate intraoperative bleeding.  Post-operative VH in eyes without 
tamponade or gas tamponade was nil (n=1), mild (n=13) or moderate (n=1). Silicone 
filled eyes had nil (n=1), moderate (n=3) or severe haemorrhages (n=1). Post-operative 
VA was unchanged (n=2) (10%), improved (n = 14) (70%) or worsened (n=4). VA was 
2/60 or better (n=15) to no light perception (n=1). Two eyes achieved 6/12 or better 
vision (10%). Ten eyes (50%) had 6/36 or better vision. In conclusion, pre-operative 
intravitreal ranibizumab is safe and useful in diabetic vitrectomy and appears to help with 
perioperative bleeding leading to improvement in vision. 
 
Key words:  Ranibizumab, adjuvant, diabetic retinopathy, vitrectomy 
 
 
 
INTRODUCTION 
 
Ranibizumab (LucentisTM, Genentech Inc, 
San Francisco, US) is a humanized antigen-
binding fragment designed to inhibit all iso-
forms and active degradation products of 
vascular endothelial growth factor A (VEGF-
A) (Gaudreault et al. 2007). Ranibizumab  
(Rosenfeld et al. 2006) and other anti-VEGF 
agents such as bevacizumab (AvastinTM, 
Genetech Inc, San Francisco) and pegapta-
nib sodium (MacugenTM)  (Gragoudas et al. 
2004) have been shown to reduce neovas-
cularisation in age-related macular degene-
ration (AMD) when injected intra-vitreally.  
Diabetic vitrectomy is complicated by poor 
visualisation by the surgeon as a result of 
haemorrhage due to active neovascularisa-
tion. Post-operative vitreous haemorrhage is 
a further complication, resulting in de-
creased visual acuity as a result of bleeding 
particularly from optic disc neovascularisa-
tion, which cannot be directly cauterised.  
A number of case series utilizing intra-
ocular injection of bevacizumab, a drug 
designed for systemic anti-cancer use as an 
“off-label” adjunct to reduce retinal neovas-
cularisation prior to diabetic vitrectomy have 
been published (Yeoh et al. 2008). Bevaci-
zumab has been shown to induce rapid 
regression of retinal and iris neovasculariza-
tion in proliferative diabetic retinopathy 
(PDR) (Avery et al. 2006). 
Therefore, the aim of our study was to in-
vestigate the safety and benefit of giving an 
intraocular injection of ranibizumab, a drug 
designed and licensed for intraocular injec-
tion for AMD, prior to diabetic vitrectomy to 
reduce the intraoperative and post-operative 
bleeding in the eye. There has been no 
such study to date. 
 
MATERIALS AND METHODS 
 
A retrospective study was performed at 
the Universiti Kebangsaan Malaysia 
Medical Centre (UKMMC). The medical 
records of 16 diabetic patients were re-
viewed. These eyes received 20 consec-
utive ranibizumab injections from July 
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2007 to February 2009 prior to vitrec-
tomy.  
All patients were known diabetics diag-
nosed by a physician and were on treat-
ment with including oral hypoglycaemics 
and/or insulin injections. Each study eye 
had known or suspected diabetic retino-
pathy. Pre-operative intravitreal ranibi-
zumab was considered for all patients who 
had never received any prior laser 
photocoagulation or in whom laser pho-
tocoagulation could not be completed due 
to significant areas of retinal detachment. It 
was also considered for patients with 
clinically significant macular oedema 
secondary to vitreo-macular traction. This 
included patients with vitreous 
haemorrhage, tractional retinal detachment 
(TRD) with or without rhegmatogenous 
component, vitreomacular traction (VMT) 
and epiretinal membrane (ERM) secondary 
to known or suspected proliferative diabetic 
retinopathy (PDR) with active 
neovascularisation. When the fundus could 
not be viewed, B scan ultrasonography 
was used to confirm the diagnosis. 
Patients with prior history of cerebro-
vascular accident (CVA) or known vas-
cular occlusion of any kind were ex-
cluded from injection with of ranibizumab. 
Injection was only scheduled after the 
routine pre-operative investigations 
which included blood pressure reading, 
full blood count, renal profile, fasting 
blood glucose level, echocardiogram and 
chest X ray were acceptable for general 
or local anaesthesia as the injection was 
considered a commitment towards 
operation. 
Informed consent was obtained from 
each patient. This included counseling on 
the risk of infection, cataract and retinal 
detachment. Each injection was per-
formed in a clean treatment room in the 
eye clinic outpatient setting according to 
strict aseptic technique. Anaesthesia for 
the procedure was topical with guttae 
proparacaine hydrochloride (AlcaineTM) 
and subconjunctival anaesthesia with 2% 
lignocaine (XylocaineTM). Subsequently, 
5% povidone iodine lid scrub and douche 
was performed prior to sterile draping. All 
patients received ranibizumab, which 
was aspirated by the assistant into a new 
30G insulin needle after swabbing each 
bottle cap with 100% alcohol wipe.  
Each injection of 0.05 or 0.1 ml of rani-
bizumab was given 4 mm from the lim-
bus in phakic patients and 3.5 mm in 
pseudophakic patients while directing the 
injection into the centre of the vitreous 
cavity. Five percent iodine was then re-
instilled onto the ocular surface. The pa-
tient then received guttae ciprofloxacin 
eyedrops at 2 hourly intervals for one 
week. They were given instructions on 
symptoms and signs of endophthalmitis 
and were reviewed the following day and 
on the day of admission for surgery. 
Demographical data (age, gender and 
ethnicity) were recorded. Dates of intra-
vitreal injections, volume of drug injected, 
surgical indications, operation record of 
intraoperative bleeding and duration of 
surgery were noted. Three cases in which 
anti-VEGF had been injected at any time 
in the past were excluded from further 
analysis. The pre-operative visual acuity 
prior to injection and on admission was 
noted and the post-operative visual acuity 
was also noted at one week, one month, 3 
months, 6 months after the operation and 
at last review. The clarity of ocular media 
was noted from the diagrams and 
comments in the operative notes and this 
was correlated with the visual acuity. 
Post-operative haemorrhage was 
graded as “nil”, if all retina details were 
visible; “mild” if any part of the fundus 
was slightly obscured with blood vessels, 
optic disc and /or laser marks visible; 
“moderate” if any part of the fundus was 
totally obscured and “severe”, if the en-
tire fundus was totally obscured. The 
fundus under gas was used for assess-
ment in gas-injected eyes. Any complica-
tion of the intravitreal injection was noted. 
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RESULTS 
 
Fourteen eyes of fourteen patients re-
ceived intravitreal injection of 0.05 (0.5 
mg) to 0.1 ml (1mg) of ranibizumab be-
tween 3 to 8 days prior to vitrectomy by 
two surgeons (Table 1). Mean duration of 
injection prior to surgery was 4.4 days. 
One patient received 1 mg of ranibizu-
mab. One patient received injection prior 
to PPV in both eyes. Patient ages ranged 
from 46 to 72 years with a mean of 57.7 
years. There were 5 males and 11 fe-
males. Twelve patients were Malay, 3 
were Chinese and 1 was Indian. Twelve 
were right eyes (Table 1). 
There were no complications locally or 
systemically post-injection. Indications for 
vitrectomy were retinal detachment in 11 
eyes of whom 3 were combined TRD and 
rhegmatogenous RD (RRD) with macula 
detached and 8 were tractional detach-
ments involving the macula. Three trac-
tional detachments were in combination 
with vitreous haemorrhage while there 
were eleven pre-operative vitreous hae-
morrhages. One eye had vitreo-macular 
traction syndrome secondary to PDR. 
One eye had re-bled 3 years after pre-
vious vitrectomy for TRD. Pre-operative 
visual acuity (VA) ranged from 6/36 to 
perception of light with the majority (19 
eyes) with pre-operative vision of 6/60 or 
worse. 
Pars planar vitrectomy (PPV) was per-
formed in all cases under local (n=17) or 
general anaesthesia (n=3) by 2 surge-
ons. 20G vitrectomy was performed pri-
marily in 15 cases and 23G in 5 cases 
depending on instrument availability and 
surgeon preference. Panretinal laser 
photocoagulation (PRP) was topped up 
or given to the ora in all cases. Intraocu-
lar tamponade of silicone oil 1300Cs was 
used in 5 cases and intraocular gas tam-
ponade was used in 7 cases. Of those 
under gas tamponade, sulphur hexafluo-
ride (SF6) was used in 5 cases, and oc-
tafluoropropane (C3F8) in 2 cases (Table 
2). 
All eyes had minimal to moderate intra-
operative bleeding. The amount of intra-
operative bleeding did not correlate with 
duration of injection prior to vitrectomy 
but more with the age of the patient and 
activity of neovascularisation. There was 
no documented case of progression of 
tractional detachment to RRD during the 
study period although fibrosis of neovas-
cularisation was consistently observed to 
various degrees in patients with view of 
the retina. Mild progression of the TRD 
not resulting in RRD accompanied fibro-
sis in 3 observable cases (Table 3). 
Post-operative VH in eyes without tam-
ponade or with subtotal gas tamponade 
ranged from nil (n=1), mild (n=12) to 
moderate (n=1) with complete clearance 
4 to 90 days post-operatively (mean 21 
days). There was one case of slightly 
increased post-operative VH at 1 week, 
which cleared by 1 month during the 
study period. 
Silicone oil filled eyes had nil (n=1) to 
moderate localized preretinal haemorr-
hages behind the oil (n=3) to severe 
post-operative haemorrhage  (n=1), 
which cleared after an average of 44.8 
days including one which took over 3 
months to clear with oil pushed into the 
anterior chamber. We believe the pa-
tient’s uncontrolled hypertension was re-
sponsible for this outcome as haemosta-
sis was achieved at the end of the oper-
ation. Two silicone filled eyes had very 
minimal haemorrhages and clear fundal 
view. Duration of follow-up ranged from 1 
month (n=19) to 14 months with 18 eyes 
(90%) having 3 or more months of follow-
up. There were 2 patients who defaulted 
follow-up after 1 and 3 months. (Table 3) 
In general, post operative VH cleared in 
mean time of 17.6 days for 23G vitrec-
tomy and 30.1 days (n=10) for 20G vi-
trectomy (Table 3). VA had either re-
mained unchanged (n=2) (10%),  
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Table 1: Showing patient demographics. 
  
improved (n = 14) (70%) or worsened 
(n=4) with best corrected VA at last 
review ranging from 2/60 or better (n=15) 
to no perception of light (n=1). Two eyes 
achieved 6/12 or better vision (10%). 
Two eyes gained significant vision from 
hand motions or counting fingers to as 
much as 6/9 vision. Ten eyes (50%) 
achieved 6/36 or better vision. Mean gain 
in visual acuity was 1.8 Snellen lines. 
However, 60% of 23G eyes gained at 
least 3 Snellen lines compared to 46% of 
20G eyes. 
Two eyes (10%) developed retinal de-
tachment post-operatively. One patient 
developed total retinal detachment one-
month post PPV with gas injection. He 
underwent further operation and retinal 
reattachment surgery. Another case de-
veloped retinal detachment following cat-
aract extraction and silicone oil removal. 
There was no emergence or exacerba-
tion of rubeosis in the any of the eyes at 
6 months postoperatively. 
 
DISCUSSION 
 
Diabetic retinopathy (DR) is the leading 
cause of blindness among people of 
working age worldwide, leading to signifi-
cant loss of quality of life. During the first 
two decades of disease onset, nearly all 
Type 1 diabetic patients and over 60% of 
type 2 diabetics have retinopathy. In the 
Wisconsin Epidemiologic Study of Dia-
betic Retinopathy (WESDR), 3.6% of 
younger-onset patients (type 1 diabetes) 
and 1.6% of older-onset patients (type 2 
Eye Patient 
Age 
(yrs) 
Gender Ethnicity 
Duration 
of 
Follow- 
Up (mths) 
 Legend:  
M-male 
F-female 
1-Malay 
2-Chinese 
3-Indian 
 
1 A 55 F 1 6 
2 B 46 M 1 14 
3 C 57 F 1 1 (defaulted) 
4 D 52 F 1 3 
5 E 65 M 1 3 (defaulted) 
6 F 55 F 1 6 
7 G 55 F 1 6 
8 H 72 F 2 3 
9 I 65 M 2 3 
10 J 56 F 1 9 
11 J 56 F 1 10 
12 K 49 M 3 3 
13 L 57 M 1 12 
14 L 57 M 1 9 
15 M 61 M 1 3 
16 M 61 M 1 1.5 
17 N 65 F 2 3 
18 O 53 M 1 9 
19 O 53 M 1 6 
20 P 60 F 1 5.5 
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Table 2: Showing procedures performed on patients in the study. 
Eye Patient Indication(s) Volume of Lucentis 
Duration prior 
to Vitrectomy 
(days) 
Operation performed 
1 A 1 0.1ml 4 23G PPV/EL 
2 B 2,3 0.05 ml 5 20G PPV/MP/EL/SO 
3 C 2 0.05 ml 4 20G PPV/MP/EL/SO 
4 D 1 0.05 ml 4 PEA/IOL/23G PPV/EL 
5 E 2 0.05 ml 4 PEA/IOL/23G PPV/EL/SF6 
6 F 2 0.05 ml 3 PEA/IOL/20 G PPV/EL 
7 G 1 0.05 ml 4 20G PPV/EL 
8 H 1 0.05 ml 4 PEA/IOL/23G PPV 
9 I 1,2 0.05 ml 3 23G PPV/MP/EL/Ret/C3F8 
10 J 2 0.05 ml 3 20GPPV/EL/SO 
11 J 2 0.05 ml 4 20GPPV/EL/C3F8 gas 
12 K 2,3 0.05 ml 3 20GTPPV/MP/EL/Cryo/SO 
13 L 1 0.05 ml 6 20G PPV/MP/SF6/IVTA 
14 L 4 0.05 ml 8 20G PPV/MP/SF6 
15 M 2 0.05 ml 6 20G PPV/SO 
16 M 1,2,3 0.05 ml 7 PEA/20G PPV/SO 
17 N 1,2 0.05 ml 4 PEA/20G PPV/IOL/EL/SF6 
18 O 1 0.05 ml 4 20G PPV/MP/SF6 
19 O 1 0.05 ml 4 20G PPVMP/EL 
20 P 1 0.05 ml 4 20G PPV/EL 
 
1-Vitreous haemorrhage, 2- Tractional retinal detachment (RD), 3-Rhegmatogenous RD, 4-Vitreomacular 
traction, PPV- Pars planar vitrectomy, PEA/IOL-Phaco-Emulsification + intraocular Lens implant, MP-
membrane peeling, EL-endolaser, Cryo-cryotherapy, Ret-retinectomy, SF6-sulphur hexafluoride, C3F8-
octafluoropropane, SO-silicone oil 
 
diabetes) were legally blind (Klein et al. 
2007). 
The standard treatment for proliferative 
diabetic retinopathy (PDR) is PRP, which 
ablates large areas of retina in order to 
reduce hypoxia. However, in progressive 
vasoproliferative disorders such as dia-
betes, and when extensive new vessels 
or vitreous haemorrhage preclude fundus 
visualization and photocoagulation, pars 
plana vitrectomy becomes the only pos-
sible approach to prevent permanent vis-
ual loss. 
Approximately 4.5% of patients with 
PDR require pars plana vitrectomy (Flynn 
et al. 1992) despite prior PRP to remove 
vitreous opacities and fibrovascular 
membranes and relieve vitreous traction 
with the first goal being to restore vision 
(The Diabetic Retinopathy Vitrectomy 
Study Group 1985; The Diabetic 
Retinopathy Vitrectomy Study Group 
1988). 
Despite advances in vitreous surgery, in 
cases of PDR, the main problem during 
vitrectomy is intraoperative bleeding 
(Peyman et al. 1976) which could ad-
versely affect surgical outcome (Lee & 
Abrams 2001). Other complications include 
retinal detachment because of iatrogenic 
breaks, early postoperative haemorrhage 
and neovascular glaucoma related to lens 
removal (Lee & Abrams 2001). 
The usage of intravitreal ranibizumab in 
our study was able to reduce intraopera-
tive bleeding, an observation comparable 
to studies by Yang et al. (2008) and 
Oshima et al. (2008) who conducted 
studies with another anti-VEGF agent, 
bevacizumab. Furthermore, the usage of 
ranibizumab in the setting of 23G vitrec-
tomy appears to halve the duration of 
post-operative vitreous haemorrhage 
when compared to 20G vitrectomy. This 
result is comparable to the experience 
with bevacizumab when used in diabetic 
vitrectomy (Yang et al. 2008) supporting 
a safe and effective role for ranibizumab. 
Visual acuity cannot be used alone in 
the evaluation of outcome following dia 
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betic vitrectomy due to the compounding 
factors of cataract, macular oedema and 
macular ischaemia. Visual acuity in our 
study group improved in up to 50% of 
eyes with a mean gain of 1.8 Snellen 
lines. Interestingly, the proportion of 23G 
vitrectomy eyes gaining 3 lines of vision 
was higher than eyes undergoing 20G 
vitrectomy at final review. This finding is 
similar to that of Oshima et al. (2008) 
who found a higher proportion of eyes 
gaining 3 lines of vision with smaller inci-
sion vitrectomy reflecting a clear advan-
tage of the usage of 23G vitrectomy in 
combination with anti-VEGF. 
Vascular endothelial growth factors 
(VEGF), increase vessel permeability by 
increasing the phosphorylation of tight 
junction proteins. VEGF levels in the ret-
ina and vitreous of human eyes correlate 
with severity of PDR (Aiello et al. 1994). 
Ranibizumab “LucentisTM” (49 kDa) 
has a terminal half-life of 2.9 days in the 
ocular compartments with low systemic 
exposure, measuring less than 0.01% of 
vitreous exposure and is able to pene-
trate all retinal layers. Increased retinal 
and vitreous VEGF-A levels were ob-
served in ischaemic retinopathies in-
duced by oxidative damage and hypoxia 
(Krzystolik et al. 2002). While studies on 
immortalised bovine retinal endothelial 
cells (iBREC), show that ranibizumab re-
verses VEGF-induced cell migration and 
proliferation (Deissler et al. 2008), it also 
causes retinal arteriole vasoconstriction. 
Although ranibizumab is able to reduce 
bleeding through vasoconstriction 
(Papadopoulou et al. 2009), the already 
compromised circulation of the diabetic 
retina may be further compromised. 
Hence further studies are required to ad-
dress this delicate issue and its impact 
on case selection.  
Bevacizumab (AvastinTM) (149kDa) on 
the other hand, was designed as a che-
motherapeutic agent which acts to inhibit 
tumour angiogenesis such as in cases of 
metastatic colonic or rectal carcinoma 
(Ferrara et al. 2004). Bevacizumab is a 
humanized monoclonal antibody that 
binds to all isoforms of VEGF and is sig-
nificantly cheaper than ranibizumab. Off-
label usage of intravitreal bevacizumab 
has been documented in the literature as 
an effective adjunct for diabetic vitrec-
tomy, in numerous retrospective reviews 
(Yeoh et al. 2008). 
Ranibizumab has a faster clearance 
rate from the eye and lower systemic ab-
sorption than bevacizumab (Gaudreault 
et al. 2007). Systemic pharmacokinetics 
from the primate suggest that ranibizu-
mab is cleared up to forty times more 
rapidly from the serum than bevacizu-
mab. This suggests ranibizumab is a 
safer alternative particularly in terms of 
the risk from stroke, which is higher in 
patients taking anti-VEGF agents. This 
has potential advantages for diabetics 
who are already at risk for thromboem-
bolic events due to the associated 
atherosclerosis and concurrent hyperten-
sion and hyperlipidaemia. There were no 
thromboembolic complications from 
stroke or acute coronary event in this 
small series, a reflection of the small, 
less than 300 times smaller dose used 
intraocularly than systemic bevacizumab. 
Chen & Park (2006) have reported a 
case of pre-operative bevacizumab use 
in a 27 year old diabetic with tractional 
detachment and active vascularisation. 
They encountered minimal bleeding dur-
ing segmentation and subsequent de-
lamination of the membranes. We have 
noted a similar beneficial effect in all our 
patients with neovascularisation and fi-
brous proliferation with and without trac-
tional retinal detachment who received 
ranibizumab prior to vitrectomy.  
There are no published data on the du-
ration prior to vitreo-retinal surgery that 
the intravitreal injection should be given. 
Most surgeons would recommend that 
the surgery be undertaken no more than 
10-14 days after anti-VEGF injection as 
the time from injection to TRD is 13 days 
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(range: 3-31 days). We found that ranibi-
zumab had a beneficial effect when in-
jected from 3 days to 8 days prior to 
PPV. Bleeding was mild to moderate in-
traoperatively when given closer to PPV 
but bleeding could be very little at 8 days 
or more between 6 to 7 days. As long as 
this duration is not exceeded, it appears 
that the activity of the pre-existing ne-
ovascularisation was more important 
than the duration.  
Rhegmatogenous retinal detachment 
occurs in a small percentage of patients 
after PPV with or without gas tamponade 
for vitreous hemorrhage or tractional reti-
nal detachment caused by proliferative 
diabetic retinopathy at a rate of 4.3% 
(Schrey et al. 2006). Our rate of 10% of 
retinal detachment may represent a small 
subgroup of patients in which there was 
progression of the tractional detachment, 
for which ranibizumab should be used 
carefully. 
The incidence of endophthalmitis in in-
travitreal injections of anti-VEGF agents 
is low at approximately 0.029% (Pilliab et 
al. 2008). There were no complications 
from the injection such as uveitis or 
endophthalmitis in this study. 
The limitations of the present study in-
clude its retrospective nature and small 
numbers. There is the ethical dilemma of 
with-holding preoperative adjunctive 
treatment with anti-VEGF agents in 
young diabetics with active neovascular 
fronds who may be randomised to the 
control group if the study design was a 
randomised, controlled trial as the risk of 
severe intraoperative bleeding is known 
in this subset of patients. The study adds 
to the wealth of information on the 
usefulness of ranibizumab in diabetic 
vitrectomy of which there are no 
published data at present. As the role of 
VEGF inhibitors is not yet established, 
randomized studies where possible are 
advocated. 
Future improvements in studies of this 
topic will include prospective studies that 
incorporate standardized documentation 
of the degree of visualisation during sur-
gery, records of the bottle height rising 
time, number of uses of endodiathermy 
and number of instrument passes for ex-
ample as well as the degree of reduction 
in bleeding intraoperatively. This may 
also include a randomised, controlled 
trial. Studies comparing ranibizumab with 
bevacizumab may also yield potential 
differences and advantages of one over 
the other. 
 
CONCLUSION 
 
In conclusion, pre-operative intravitreal 
ranibizumab is safe and useful in diabetic 
vitrectomy at least comparable in terms 
of outcome with bevacizumab. It  ap-
pears to be as helpful as bevacizumab 
with perioperative bleeding leading to 
improvement in vision.  It has a good 
safety profile systemically and locally. 
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